The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | How does the CR-SEQUENCE trial reaffirm existing guidelines in RASwt CRC?
Ramon Salazar, MD, PhD, Institut Català D’Oncologia, Barcelona, Spain, discusses how the results of a the CR-SEQUENCE trial (2024-510967-41-00) provide additional support to existing guidelines recommending the use of anti-EGFR therapy first in patients with left-sided RAS wild-type colorectal cancer (RASwt CRC). These findings offer prospective randomized data to back up previous retrospective data-based recommendations, emphasizing the effectiveness of treating such patients with anti-EGFR plus chemotherapy as the initial approach. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Guidelines already point to the recommendation to use anti-EGFR first. So our results provide additional support to these recommendations that were largely based on retrospective data. This is a new set of prospective randomized data that supports the recommendations of treating patients with left-sided RAS wild-type tumors with anti-EGFR plus chemotherapy first.
This transcript is AI-generated...
Guidelines already point to the recommendation to use anti-EGFR first. So our results provide additional support to these recommendations that were largely based on retrospective data. This is a new set of prospective randomized data that supports the recommendations of treating patients with left-sided RAS wild-type tumors with anti-EGFR plus chemotherapy first.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
